Novel Influenza A (H1N1): Where Are We? by Cheong, Hee Jin
In late March and early April, 2009, an outbreak of H1N1
influenza A virus infection was detected in Mexico, with sub-
sequent cases observed in several other countries including
the United States (1, 2). Though limited information was
available on the early pre-pandemic situation in Mexico, sub-
sequent cases in the U.S. and Canada had a common travel
history of returning from Mexico, the epicenter of the current
outbreak. After that, however, secondary cases without a trav-
el history developed in the U.S. and Canada, which spread
to the United Kingdom and Spain over several weeks with
increasing local community-wide transmission. As the days
go by, the number of infected patients and countries with
laboratory-confirmed cases is increasing. As of May 19, 2009,
there have been over 9,830 laboratory-confirmed cases in 40
countries (3).
Characteristics of Novel A/H1N1 
Current novel A/H1N1 virus has been found to contain a
unique combination of genes from pig, bird, and human flu
viruses. This peculiar recombinant influenza virus is entire-
ly new, and has not been seen before elsewhere (3). This cre-
ates an almost universal vulnerability to infection in nearly
all people. Therefore, the emergence of novel A/H1N1 infec-
tion among humans presents the greatest pandemic threat
since the 1968 pandemic caused by A/H3N2 (4). The cur-
rent pandemic alert level still remains at phase 5-just one level
short of a full pandemic. However, considering the situation
in Japan and other countries these days, raising the pandem-
ic level to 6 is imminent. 
Given that novel A/H1N1 influenza viruses nearly met
the three prerequisites for pandemic; emergence of a novel
virus with little or no pre-existing immunity in the world’s
population, the potential to infect humans causing clinically
apparent illness, and efficient transmissibility from one human
to another. Therefore, it may be quite difficult to predict how
the pandemic situation will evolve as time goes on.
Vulnerable populations 
That 60% of patients were 18 yr of age or younger suggests
that children and young adults have a higher susceptibilty to
novel A/H1N1 infection than elderly groups. Likewise, in the
early periods of the previous pandemics, young adults were
more likely to acquire A/H1N1 infection through frequent
social activities. In turn, there is a concern that those infected
young adults transmit the influenza virus to elderly of local
communities. On the other hand, it is also possible that elder-
ly may show partial protectivity against novel A/H1N1 in-
fluenza with preexisting antibodies, as proposed by 1976 swine
influenza vaccine studies (5, 6). There is a possibility of bias
in case-diagnosis may also exist, with more of the young peo-
ple being tested as part of outbreaks in schools (7) and fewer
of the elderly persons being tested for influenza. However,
the epidemic is evolving rapidly and spreading worldwide,
and the number of confirmed cases is an underestimate of
the number of cases that have really occurred. 
Clinical features 
To date, most confirmed cases of novel A/H1N1 influenza
have been characterized by mild influenza like illness (fever,
chills, headache, upper respiratory infection symptoms, myal-
gias, arthralgias and fatigue) similar to those of typical sea-
sonal influenza; the incubation period is known to range from
2 to 7 days. Gastrointestinal symptoms such as vomiting and
diarrhea have also been common (38%), both of which are
atypical of seasonal influenza (8). However, we should pay
attention to certain groups, such as infants, elderly persons,
and immunocompromised hosts, because they may present
atypical clinical manifestations. Although the full range of
complications of current A/H1N1 influenza is not yet known,
it seems to be similar to that of seasonal typical influenza: res-
piratory complications and exacerbation of underlying chron-
ic medical conditions. Several cases of respiratory failure due
to rapidly progressive pneumonia have been reported in Mex-
ico (9). In comparison, according to U.S. data, most described
infected patients have been mild, 36 (9%) required hospital-
ization and a 6% (2/36) death rate was observed among hos-
pitalized patients (8). Among 22 hospitalized U.S. patients
with available data, >50% of complicated cases have risk fac-
tors for influenza complications (8). Young children (e.g., <5
yr of age), pregnant women, and people with comorbidities
are at increased risk of influenza complications. 
Mortality
There have been 79 deaths over 9,830 laboratory-confirmed
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novel A/H1N1 cases, and overall mortality is 0.8% so far (2).
This rate is not much higher than seasonal influenza mortal-
ity. In Mexico, 72 of 3,648 laboratory-confirmed cases of A/
H1N1 influenza have been fatal (2). Most of these deaths were
related to respiratory failure. Among 5,123 cases in the Unit-
ed States, there have been five deaths (8). Among 496 cases
in Canada, one patient has died, while one patient has died
among nine cases in Costa Rica (2). All of the deaths except
in Mexico occurred in persons with chronic health problems
(3, 8), and one death in a pregnant woman was observed (10).
Antivirals for novel A/H1N1 
Novel H1N1 viruses isolated from patients in Mexico and
the United States have shown that those viruses are sensitive
to neuraminidase inhibitors, but resistant to the adamantanes
(11). However, considering current clinical features of novel
A/H1N1 infection, treatment with neuraminidase inhibitor
may not be absolutely indicated for all cases of infection. An-
tiviral treatment is recommended for all hospitalized patients
with confirmed, probable, or suspected novel H1N1 influen-
za, and patients who are at higher risk for seasonal influenza
complications. Furthermore, in the use of antiviral drugs for
prophylactic purposes, judicious decisions are necessary accord-
ing to national pandemic influenza preparedness plans. 
Perspective 
Many questions still remain unresolved. Will novel A/
H1N1 virus replace the human A/H1N1 virus as the sea-
sonal influenza virus this year? Will the virus reassort with
A/H3N2 or A/H5N1 influenza virus to make another vari-
ant? When will a new vaccine be available? 
Most of all, we should note that the novel A/H1N1 influen-
za viruses were rapidly transmitted across the continents to
multiple countries within merely one month of time. Of note
is the fact that the viruses are still spreading; therefore they
may not easily eradicable soon. Though the novel A/H1N1
influenza viruses have shown low virulence so far, there is a
chance that they might become better adapted to humans
and become more drastic, causing a large second wave of in-
fluenza during this fall-winter season in the Northern hemi-
sphere with higher mortality. At this time, without available
vaccine seed virus, there is no consensus on how much A/
novel H1N1 virus vaccine we should plan to produce. We
do not know if this vaccine will be effective for the A/H1N1
mutant of next season. Moreover, no one knows what detri-
mental effects a subsequent shortage of seasonal influenza
vaccine will have.
In conclusion, we stand enveloped in a heavy cloud now.
We should prepare for the upcoming second wave, waiting
until the clouds are cleared away. The potential damage varies
according to the degree of pandemic preparedness; thus, such
damage may be more serious in socio-economically deficient
countries. In addition to maximal preparedness in each coun-
try, worldwide collaboration is required. 
REFERENCES 
1. United States Centers for Disease Control and Prevention. Interim
guidance on antiviral recommendations for patients with novel influen-
za A (H1N1) virus infection and their close contacts. http://www.cdc.
gov/h1n1flu/recommendations.htm (Accessed May 7, 2009). 
2. World Health Organization. Influenza A (H1N1)-update 33, 19 May
2009. http://www.who.int/csr/don/2009_05_19/en/index.html (Acce-
ssed May 19, 2009). 
3. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team.
Emergence of a novel swine-origin influenza A (H1N1) virus in hu-
mans. N Eng J Med 2009; 361. 
4. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, Lindstrom
S, Gubareva LV, Deyde V, Garten RJ, Harris M, Gerber S, Vagoski
S, Smith F, Pascoe N, Martin K, Dufficy D, Ritger K, Conover C,
Quinlisk P, Klimov A, Bresee JS, Finelli L. Triple-Reassortant Swine
Influenza A (H1) in Humans in the United States, 2005-2009. N Eng
J Med 2009; 361. 
5. Cate TR, Kasel JA, Couch RB, Six HR, Knight V. Clinical trials of
bivalent influenza A/New Jersey/76-A/Victoria/75 vaccines in the
elderly. J Infect Dis 1977; 136 (Suppl): S518-25. 
6. Dolin R, Wise TG, Mazur MH, Tuazon CU, Ennis FA. Immunogenic-
ity and reactogenicity of influenza A/New Jersey/76 virus vaccines
in normal adults. J Infect Dis 1977; 136 (Suppl): S435-42. 
7. Jordan H, Mosquera M, Nair H, France A. Swine-origin influenza A
(H1N1) virus infections in a school-New York City, April 2009. MM-
WR Morb Mortal Wkly Rep 2009; 58 (Dispatch): 1-3. 
8. Centers for Disease Control and Prevention (CDC). Update: novel
influenza A (H1N1) virus infections-worldwide, May 6, 2009. 
9. Centers for Disease Control and Prevention (CDC). Outbreak of swine-
origin influenza A (H1N1) virus infection---Mexico, March--April
2009. MMWR Morb Mortal Wkly Rep 2009; 58: 467. 
10. Centers for Disease Control and Prevention (CDC). Novel influenza
A (H1N1) virus infections in three pregnant women-United States,
April-May 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 497-500. 
11. Update: drug susceptibility of swine-origin influenza A (H1N1) virus-
es, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 433-5. 
Address for correspondence
Hee Jin Cheong, M.D., Ph.D.
Division of Infectious Disease, Department of Internal Medicine, Korea University
Medical College, 97 Gurodong-gil, Guro-gu, Seoul 152-703, Korea
Tel : +82.2-2626-1104, Fax : +82.2-2626-1105
E-mail : heejinmd@korea.ac.kr
Received : 26 May 2009
Accepted : 26 May 2009